Quanterix is a biotechnology company that develops ultrasensitive biomarker detection for healthcare.
Quanterix Corporation is developing a novel platform for single-molecule analysis that will bring an unprecedented level of sensitivity, precision, and assay robustness to clinical diagnostics, drug development, and life science research. Their unique approach permits rapid quantification and analysis of individual proteins and small molecules within complex biological samples, enabling us to address a variety of unmet medical needs. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’s technology is designed to enable much earlier disease detection, better prognosis, and precise treatment methods to improve the quality of life and longevity of the population for generations to come.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 23, 2016 | Series D | $46M | 3 | ARCH Overage Fund | — | Detail |
Nov 15, 2012 | Series C | $18.50M | 1 | — | — | Detail |
Aug 25, 2008 | Series A | $15M | 1 | ARCH Venture Partners | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
ARCH Overage Fund | Yes | Series D |
Hercules Capital | — | Series D |
ARCH Venture Partners | — | Series D |